Latsipil - instructions for use, analogs, reviews and release forms (2 mg and 4 mg tablets) drugs for the treatment of hypertension or hypertension in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Lazipil. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on using Latsipil in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Latsipil in the presence of existing structural analogs. Use for the treatment of hypertension or hypertension in adults, children, as well as in pregnancy and lactation. Composition of the preparation.

Lazipil - selective blocker of slow calcium channels of 3 generations from the group of dihydropyridine derivatives. Has a specific effect mainly on the calcium channels of the smooth muscles of the vessels.

The main effects of Latsipil are the widening of peripheral arterioles, a reduction in the overall peripheral vascular resistance (OPSS), lowering of blood pressure (BP). In therapeutic doses normalizes the transmembrane flow of calcium, does not affect the venous tone, sinoatrial and atrioventricular nodes, does not have a negative inotropic effect. When prescribing the drug at a dose of 4 mg, a minimum elongation of the QT interval on the electrocardiogram is observed.

Composition

Latsidipin + auxiliary substances.

Pharmacokinetics

After oral administration, Latsipil is rapidly absorbed from the gastrointestinal tract (GIT). Absolute bioavailability is approximately 10%. The binding of lacidipine to plasma proteins is more than 95% (with albumin and alpha-1-glycoprotein). Latsidipin undergoes intensive metabolism during the "first passage" through the liver. Metabolized in the liver with the formation of 4 major metabolites,possessing insignificant pharmacological activity. There is no evidence to confirm the ability of lacidipine to induce or inhibit hepatic enzyme activity. Approximately 70% of the accepted dose of lacidipine is excreted in the form of metabolites through the intestine, the rest of the dose - in the form of metabolites with urine.

Indications

• Essential (primary) hypertension (high blood pressure) as monotherapy or as part of combination therapy with other antihypertensive agents, including beta-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors;
• secondary hypertension.

Forms of release

Tablets coated with 2 mg and 4 mg.

Instructions for use and dosing regimen

Doses are set taking into account the severity of the course of the disease and the individual reaction of the patient.

The initial dose is 2 mg once a day. If necessary, it is possible to increase the dose to 4 mg per day and then to 6 mg per day after the time that is required to achieve the full therapeutic effect. Usually in clinical practice this period is 3-4 weeks,unless the patient's condition requires a faster increase in the dose.

Lacisil should be taken at the same time of the day, preferably in the morning, regardless of food intake.

Patients with impaired liver function correction of the dose of Lacipil is not required.

Patients with impaired renal function, as well as the elderly, do not need a dose adjustment for Lacipil.

Side effect

• headache, dizziness;
• tides;
• peripheral edema;
• palpitation;
• exacerbation of angina, especially immediately after the start of treatment, which is more likely in patients with severe clinical manifestations of coronary heart disease;
• functional disorders of the stomach;
• nausea;
• hyperplasia (proliferation of the tissue) of the gums;
• reversible increase in blood levels of the enzyme alkaline phosphatase (APF);
• polyuria (increased amount of excreted urine);
• skin rash (erythema), itching;
• general weakness.

Contraindications

• aortic stenosis (constriction of the aortic aperture in the valve region);
• children and adolescents under 18 years of age (efficacy and safety not established);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Data on the safety of clinical use of lapipala in pregnancy are absent.

The use of latsipila during pregnancy and lactation is possible only in cases where the intended benefit to the mother exceeds the potential risk to the fetus or newborn.

In experimental studies on laboratory animals, it has been shown that lacidipine or its metabolites are excreted in breast milk.

Use in children

Clinical experience of using Latsipil in pediatrics is not available, therefore, it is not recommended to use the drug in patients under 18 years of age.

Application in elderly patients

The elderly are not required to adjust the dose of Lacipil.

special instructions

Lazipil does not affect the automatism of the sinoatrial node and does not slow the excitation through the atrioventricular node (AV node).

Considering the theoretical possibility of the effect of calcium channel blockers on the function of the sinoatrial and AV nodes, Lazipil should be used with caution in patients with impaired activity of these pacemakers.

Lacidipine (like other calcium channel blockers from the dihydropyridine group) should be used with caution in patients with congenital or acquired (documented) QT interval elongation.Lacipyl should be administered with caution at the same time as drugs that can induce prolongation of the QT interval, such as antiarrhythmic drugs of grades 1 and 3, tricyclic antidepressants, some neuroleptics, antibiotics (erythromycin), and some histamine H1 receptor blockers (terfenadine).

The drug should be used with caution in patients with low cardiac output, with unstable angina and after a recent myocardial infarction.

Caution is used Latsipil in patients with hepatic insufficiency, since in this category of patients the hypotensive effect of the drug may be more pronounced.

Latsipil does not interfere with glucose tolerance, does not reduce the effectiveness of antidiabetic therapy.

During the period of treatment, it is necessary to conduct a standard observation of the functional state of the myocardium and the level of arterial pressure.

Like other dihydropyridine drugs, Latsipil can not be washed down with grapefruit juice, as this can reduce its bioavailability.

Impact on the ability to drive vehicles and manage mechanisms

Data on the impact of Lazipil on the ability to drive and work with machinery are absent.

Drug Interactions

The combined use of latsipil and other antihypertensive drugs, such as diuretics, beta-blockers or ACE inhibitors, can cause an additive hypotensive effect.

With the simultaneous use of Latsipil with other commonly used antihypertensive drugs, digoxin, tolbutamide and warfarin, no specific interaction was noted.

Antihypertensive action of Latsipil weaken non-steroidal anti-inflammatory drugs (sodium retention and blockage of prostaglandin synthesis by the kidneys) and estrogens (sodium retention).

The concentration of lacidipin in the blood plasma can increase with the simultaneous administration of cimetidine.

In patients after transplantation of the kidney that received cyclosporine, Latsipil eliminates the decrease in renal blood flow and glomerular filtration rate caused by cyclosporine administration.

Analogues of the drug Lazipil

Structural analogs for the active substance:

• Lacidipine;
• Sakur.

Analogues of the drug Lazipil by pharmacological group (calcium channel blockers):

• Adalate;
• Acridipine;
• Amsaar;
• Amlovas;
• Amlodak;
• Amlodigamma;
• Amlodipine;
• Amlong;
• Ammonorm;
• Amrorus;
• Amlotop;
• Ancardard;
• Aprovask;
• Breival;
• Vylloset;
• Veracard;
• Verapamil;
• Vertizine;
• Dilcardia;
• Diltiazem;
• Diltzer;
• Dilren;
• Diltz;
• Silden;
• Isoptin;
• Kaveril;
• Caduette;
• Kalchek;
• Cardil;
• Cardilopin;
• Karmagip;
• Concor;
• Corvadil;
• Cordaflex;
• Cordipine;
• Corinfar;
• Coripren;
• Lacidipine;
• Leukoptin;
• Lernikor;
• Lozap;
• Lortense;
• Nimodipine;
• Nimopin;
• Nitremed;
• Nifébyen;
• Nifedex;
• Nifedikap;
• Nifedipine;
• Nifelate;
• Nifesan;
• Normodipine;
• Octidipine;
• Prestan;
• The Procurator;
• Racilam;
• Sakur;
• Sanfidipine;
• Stugeron;
• Tenliza;
• Tenox;
• Triapin;
• Felodip;
• Phenigidine;
• Finoptin;
• Foridon;
• Cinedal;
• Cinnasan;
• Egipres;
• Ecquard;
• Exforge;
• Exototans;
• Enanorm.

Response of a therapist

It is quite a good drug for treating patients with hypertension. Assign Lazipil to everyone with an initial dose of 2 mg per day. And if the figures for blood pressure are low, then only occasionally (about a month later) had to adjust the dose, increasing it to 4 mg per day.I have patients who receive and 6 mg per day. There were cases when at the beginning of therapy with Latsipil patients complained of a headache, palpitation, but eventually all these side symptoms spontaneously disappeared. Therefore, I can say that in my practice there were no serious side effects in patients receiving Lazipil on a regular basis.

Similar medicines:

Other medicines: